NEW YORK (GenomeWeb) – Genomics plc, an Oxford, UK-based bioinformatics company, announced today that it has inked a deal with Biogen to screen drug targets for the firm.

Genomics will use its genomic data analysis and interpretation capabilities to refine Biogen’s drug target selection. The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database and analytical expertise to uncover relationships between genetic variation and human health outcomes, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.